Preclinical studies of the anticancer vaccine CaTeVac completed in Russia
The dendritic-cell vaccine CaTeVac, developed at the N. N. Petrov National Medical Research Center of Oncology, has passed preclinical studies. Its use in patients with soft-tissue sarcomas is planned to begin in 2027, with prospects of extending it to melanoma, kidney cancer and CNS tumors.
Otabek Yusupov